Is compressed colchicine tablet superior to other colchicine preparations in patients with familial Mediterranean fever?

Vasi İ., Kardaş R. C., Yıldırım D., Kaya B., Duran R., Karadeniz H., ...Daha Fazla

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, cilt.62, ss.77-82, 2024 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 62
  • Basım Tarihi: 2024
  • Doi Numarası: 10.5414/cp204494
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, Veterinary Science Database
  • Sayfa Sayıları: ss.77-82
  • Gazi Üniversitesi Adresli: Evet

Özet

Aims: The aim of our study is to evaluate the differences in effectiveness, dosage, and side effect profiles in the use of colchicine preparations and evaluate the superiority of compressed colchicine tablets in familial Mediterranean fever (FMF) patients with resistance or intolerance to coated colchicine tablets. Materials and methods: Patients who were diagnosed with FMF according to the Tel Hashomer criteria, aged 18 years and older, and switched from compressed colchicine to coated colchicine tablets in the rheumatology clinic of Gazi University were identified. The daily colchicine dose and FMF attack frequency before and after switching from coated colchicine tablets to compressed colchicine tablets were compared. Results: The study included 43 female (72.9%) and 16 male patients (27.1%), and the mean age was 34.54 +/- 8.3 years. The number of attacks per year was significantly reduced after switching to compressed colchicine tablets, and daily colchicine doses were lower after switching to compressed colchicine tablets (1.97 +/- 0.23 vs 1.78 +/- 0.39 mg, p < 0.001). Conclusion: Compressed colchicine tablets were shown to be superior to other colchicine preparations and compressed colchicine tablets to be a useful treatment option before initiating biological agents in patients who were unresponsive to coated colchicine.